ArticleScientific reports2024
Prevalence and in vitro study of human polyomavirus 9.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Little is known about human polyomavirus 9 (HPyV9). The mode of transmission and the site of replication are unknown, and seroprevalence data have been published with a wide range. A total of 1038 serum samples from individuals aged 0.7-93 years were used for seroprevalence study. We observed that seropositivity increased with age among children and young adults, and a 36.2% adult seroprevalence was detected. The prevalence was examined in samples from the respiratory tract: cancerous and non-cancerous lung tissues, tonsils, adenoids, throat swabs, middle ear discharge and nasopharyngeal samples collected from children and adults. HPyV9 was detected in 5.2% of nasopharyngeal samples and 1% of tonsils. Upon a viral infection, the interaction of viral promoters and cellular factors may determine whether a virus productively replicates in a cell. The early and late promoter activity of HPyV9 and the effect of the large T antigen (LTAg) on it was investigated in respiratory, kidney, endothelial and colon cell lines, fibroblast and primary airway epithelial cells. The highest promoter activity was measured in A549 lung cell line. LTAg expression significantly increased the late promoter activity. Based on our results, the respiratory cells may be suitable for HPyV9 replication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.